ProductUpdated on 30 June 2025
AKicell Monocyte Cell Therapy
About
Akicell is the first application of an autologous advanced cell therapy platform that is produced at a centralized facity. It is a therapy that does not fight against a specific molecular mechanism or pathway, but favors a decrease of inflammation and activates simultaneously mechanisms regenerating damaged tissue, thus avoiding or significantly decreasing the processes of necrosis and fibrosis that follow kidney aggression. We gather the patient's blood and return our medicine to the hospital within 36 hours to treat the patient with a GMP quality ready to administer medicine.
Applies to
- Pharmaceutical industry
- Laboratory industry
Organisation
Similar opportunities
Service
Raquel Rodriguez
Technology Transfer and Innovation Promotion Specialist at Universidad de Alcalá
Alcalá de Henares, Spain
Service
Precision Oncology and Antitumour Therapies
Raquel Rodriguez
Technology Transfer and Innovation Promotion Specialist at Universidad de Alcalá
Alcalá de Henares, Spain
Product
NeoMag: Revolutionize your research with accurate biomechanical modeling
- Other
- Distribution Partner
- Laboratory industry
- Pharmaceutical industry
Ricardo de la Torre
CEO at 60Nd
Madrid, Spain